vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Civeo Corp (CVEO). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $161.6M, roughly 1.5× Civeo Corp). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -4.0%, a 15.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 7.1%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $14.5M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -1.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.
ANIP vs CVEO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $161.6M |
| Net Profit | $27.5M | $-6.5M |
| Gross Margin | — | 22.7% |
| Operating Margin | 14.1% | -0.1% |
| Net Margin | 11.1% | -4.0% |
| Revenue YoY | 29.6% | 7.1% |
| Net Profit YoY | 367.5% | 58.1% |
| EPS (diluted) | $1.14 | $-0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $161.6M | ||
| Q3 25 | $227.8M | $170.5M | ||
| Q2 25 | $211.4M | $162.7M | ||
| Q1 25 | $197.1M | $144.0M | ||
| Q4 24 | $190.6M | $151.0M | ||
| Q3 24 | $148.3M | $176.3M | ||
| Q2 24 | $138.0M | $188.7M | ||
| Q1 24 | $137.4M | $166.1M |
| Q4 25 | $27.5M | $-6.5M | ||
| Q3 25 | $26.6M | $-455.0K | ||
| Q2 25 | $8.5M | $-3.3M | ||
| Q1 25 | $15.7M | $-9.8M | ||
| Q4 24 | $-10.3M | $-15.4M | ||
| Q3 24 | $-24.2M | $-5.1M | ||
| Q2 24 | $-2.3M | $8.2M | ||
| Q1 24 | $18.2M | $-5.1M |
| Q4 25 | — | 22.7% | ||
| Q3 25 | — | 25.7% | ||
| Q2 25 | — | 25.3% | ||
| Q1 25 | — | 20.4% | ||
| Q4 24 | — | 18.6% | ||
| Q3 24 | — | 21.4% | ||
| Q2 24 | — | 25.4% | ||
| Q1 24 | — | 21.5% |
| Q4 25 | 14.1% | -0.1% | ||
| Q3 25 | 15.9% | 4.1% | ||
| Q2 25 | 6.6% | 1.7% | ||
| Q1 25 | 13.3% | -3.8% | ||
| Q4 24 | -2.3% | -6.7% | ||
| Q3 24 | -13.8% | 0.0% | ||
| Q2 24 | 3.7% | 6.9% | ||
| Q1 24 | 14.8% | -1.1% |
| Q4 25 | 11.1% | -4.0% | ||
| Q3 25 | 11.7% | -0.3% | ||
| Q2 25 | 4.0% | -2.0% | ||
| Q1 25 | 8.0% | -6.8% | ||
| Q4 24 | -5.4% | -10.2% | ||
| Q3 24 | -16.3% | -2.9% | ||
| Q2 24 | -1.7% | 4.4% | ||
| Q1 24 | 13.2% | -3.1% |
| Q4 25 | $1.14 | $-0.58 | ||
| Q3 25 | $1.13 | $-0.04 | ||
| Q2 25 | $0.36 | $-0.25 | ||
| Q1 25 | $0.69 | $-0.72 | ||
| Q4 24 | $-0.45 | $-1.04 | ||
| Q3 24 | $-1.27 | $-0.36 | ||
| Q2 24 | $-0.14 | $0.56 | ||
| Q1 24 | $0.82 | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $14.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $174.4M |
| Total Assets | $1.4B | $477.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $14.4M | ||
| Q3 25 | $262.6M | $12.0M | ||
| Q2 25 | $217.8M | $14.6M | ||
| Q1 25 | $149.8M | $28.4M | ||
| Q4 24 | $144.9M | $5.2M | ||
| Q3 24 | $145.0M | $17.9M | ||
| Q2 24 | $240.1M | $7.4M | ||
| Q1 24 | $228.6M | $16.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $43.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $174.4M | ||
| Q3 25 | $505.8M | $182.5M | ||
| Q2 25 | $436.8M | $209.4M | ||
| Q1 25 | $418.6M | $220.7M | ||
| Q4 24 | $403.7M | $236.4M | ||
| Q3 24 | $405.9M | $282.2M | ||
| Q2 24 | $455.8M | $297.4M | ||
| Q1 24 | $452.0M | $297.4M |
| Q4 25 | $1.4B | $477.4M | ||
| Q3 25 | $1.4B | $491.1M | ||
| Q2 25 | $1.3B | $508.8M | ||
| Q1 25 | $1.3B | $423.8M | ||
| Q4 24 | $1.3B | $405.1M | ||
| Q3 24 | $1.3B | $477.6M | ||
| Q2 24 | $920.8M | $483.2M | ||
| Q1 24 | $914.5M | $513.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $19.3M |
| Free Cash FlowOCF − Capex | $29.1M | $14.5M |
| FCF MarginFCF / Revenue | 11.8% | 8.9% |
| Capex IntensityCapex / Revenue | 0.5% | 3.0% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $19.3M | ||
| Q3 25 | $44.1M | $13.8M | ||
| Q2 25 | $75.8M | $-2.3M | ||
| Q1 25 | $35.0M | $-8.4M | ||
| Q4 24 | $15.9M | $9.5M | ||
| Q3 24 | $12.5M | $35.7M | ||
| Q2 24 | $17.4M | $32.4M | ||
| Q1 24 | $18.3M | $6.0M |
| Q4 25 | $29.1M | $14.5M | ||
| Q3 25 | $38.0M | $8.2M | ||
| Q2 25 | $71.8M | $-6.8M | ||
| Q1 25 | $32.5M | $-13.7M | ||
| Q4 24 | $13.5M | $1.8M | ||
| Q3 24 | $7.7M | $28.2M | ||
| Q2 24 | $13.0M | $27.0M | ||
| Q1 24 | $13.7M | $372.0K |
| Q4 25 | 11.8% | 8.9% | ||
| Q3 25 | 16.7% | 4.8% | ||
| Q2 25 | 34.0% | -4.2% | ||
| Q1 25 | 16.5% | -9.5% | ||
| Q4 24 | 7.1% | 1.2% | ||
| Q3 24 | 5.2% | 16.0% | ||
| Q2 24 | 9.4% | 14.3% | ||
| Q1 24 | 10.0% | 0.2% |
| Q4 25 | 0.5% | 3.0% | ||
| Q3 25 | 2.7% | 3.3% | ||
| Q2 25 | 1.9% | 2.8% | ||
| Q1 25 | 1.3% | 3.7% | ||
| Q4 24 | 1.3% | 5.1% | ||
| Q3 24 | 3.2% | 4.2% | ||
| Q2 24 | 3.2% | 2.8% | ||
| Q1 24 | 3.3% | 3.4% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.93× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CVEO
Segment breakdown not available.
